Fixed-dose-rate gemcitabine: A viable first-line treatment option for advanced pancreatic and biliary tract cancer

Oncologist

Volumn 15, Issue 2, 2010, Pages

  Milella, Michele ^a   Gelibter, Alain J ^a   Pino, Maria Simona ^a   Bossone, Giandominik ^a   Marolla, Paolo ^a   Sperduti, Isabella ^a   Cognetti, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

First line treatment; Fixed dose rate; Gemcitabine; Pancreatic cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CA 19-9 ANTIGEN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BILIARY TRACT CANCER; CANCER PATIENT; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PANCREATIC DUCTAL ADENOCARCINOMA; POPULATION; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77649157278     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0135     Document Type: Article

References (8)

1. Veltkamp SA, Beijnen JH, Schellens JH. Prolonged versus standard gemcitabine infusion: Translation of molecular pharmacology to new treatment strategy. The Oncologist 2008;13:261-276.
2. Burris H 3rd, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: Targeting the epidermal growth factor and vascular endothelial growth factor pathways. The Oncologist 2008;13:289-298.
3. Gelibter A, Malaguti P, Di Cosimo S et al. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer 2005;104:1237-1245.
4. Storniolo AM, Enas NH, Brown CA et al. An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85:1261-1268.
5. Tempero M, Plunkett W, Ruiz Van Haperen V et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402-3408.
6. Poplin E, Levy DE, Berlin J et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 2006;24:LBA4004.
7. Kiba T, Nishimura T, Matsumoto S et al. Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology 2006;70:358 -365.
8. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:Arandomized trial. J Clin Oncol 1997;15:2403-2413.